QLT Inc.
887 Great Northern Way
Suite 101
Vancouver,
BC V5T 4T5
Canada - Map
Phone: 604-707-7000
Fax: 604-707-7001
Web Site: http://www.qltinc.com
| QLT Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of pharmaceutical products, primarily in the field of ophthalmology. It offers Visudyne, a photosensitizer to treat the eye disease, known as wet age related macular degeneration; and also used for the treatment of subfoveal CNV due to pathologic myopia, or severe near-sightedness, and presumed ocular histoplasmosis or other macular diseases. The company also offers Eligard product line that includes one, three, four, and six month commercial formulations of Atrigel technology combined with leuprolide acetate for the treatment of prostate cancer. Its products in development include Visudyne therapy; punctal plug drug delivery system, an invasive drug delivery system for delivering various drugs topically to the eye through controlled sustained release to the tear film, under Phase II studies targeting the treatment of glaucoma and ocular hypertension; and QLT091001, a Phase Ia orally administered synthetic retinoid replacement therapy for 11-cis-retinal, which is a key biochemical component of the visual retinoid cycle. The company was founded in 1981 and is headquartered in Vancouver, Canada. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Robert L. Butchofsky , 47
Chief Exec. Officer, Pres |
N/A
| N/A | Mr. Cameron R. Nelson , 43
Chief Financial Officer, Principal Accounting Officer and VP of Fin. |
$
449.00K | N/A | Ms. Linda M. Lupini , 49
Sr. VP of HR & Organizational Devel. |
$
377.00K | N/A | Dr. Alexander R. Lussow Ph.d., 46
Sr. VP of Bus. Devel. & Commercial Operations |
$
415.00K | N/A | Mr. Sean Moriarty ,
Pres of QLT USA INC |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
1.48% Nasdaq 
0.32 (7.11%) 
Profile
